Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for AL001 in Bipolar disease. The expected timing is based on the latest available company guidance and may change.
10/2/23- Study may proceed issued by FDA. 3/3/25 Partners w/Massachusetts General Hospital. 7/23/25- Initiate Ph2 trial in early 2026. 03/16/26:- Initiated Ph2 BD type 1 head-to-head crossover study. Topline data expected Q3 2026.
Verification
Confirm timing and program details against the company announcement or filing.